Psygen Industries Ltd.

Recent News

  • CORRECTION FROM SOURCE: Psygen Announces use of Psilocybin in Human Trial and Provides Update on IP Portfolio

    patent applications filed for manufacturing processespatent-pending technology aims to improve yields and ultimately marginsCalgary, Alberta--(Newsfile Corp. - October 6, 2021) - Psygen Industries Ltd. ("Psygen" or the "Company") provided an update today on use of psilocybin in humans and on its intellectual property portfolio. Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured by Psygen personnel working with a third-party licensed dealer. The Company is also announcing that Psygen has developed patent-pending technology that...

    2021-10-06 7:09 PM EDT
  • Psygen Announces That Psilocybin from Its Patent-Pending Process Has Been Used in Human Trial

    patent applications filed for manufacturing processes patent-pending technology aims to improve yields and ultimately marginsCalgary, Alberta--(Newsfile Corp. - October 6, 2021) - Psygen Industries Ltd. ("Psygen" or the "Company") provided an update today on its intellectual property portfolio and on use of psilocybin in humans. Psygen is excited to announce that psilocybin recently used in a clinical trial was manufactured using Psygen's patent-pending synthetic method. The Company believes that Psygen's patent-pending technology will improve yields and margins on revenue, and that...

    2021-10-06 8:00 AM EDT
  • Psygen Announces Successful Closing of Oversubscribed Convertible Debenture Financing, Sets Value at $30mm

    Calgary, Alberta--(Newsfile Corp. - August 5, 2021) - Psygen Industries Ltd. ("Psygen" or the "Company") announced today that it has closed its previously announced non-brokered private placement financing (the "Offering") of unsecured convertible debentures (the "Debentures") for gross proceeds of $5.5 million. The Debentures incur interest of 8.0% per annum. The proceeds will allow Psygen to hire key employees and complete their 17,000 square foot facility, which is anticipated to be the first GMP compliant manufacturing facility...

    2021-08-05 8:00 AM EDT
  • Psygen Industries Ltd. and 1290442 B.C. Ltd. Announce Execution of Definitive Agreement for Reverse Takeover Transaction

    Vancouver, British Columbia--(Newsfile Corp. - April 19, 2021) - Further to the press release of Psygen Industries Ltd. ("Psygen") and Larose Ventures Ltd. dated March 24, 2021, Psygen and 1290442 B.C. Ltd. ("1290") are pleased to announce they have entered into an amalgamation agreement (the "Amalgamation Agreement") dated April 16, 2021, pursuant to which Psygen and a newly-formed wholly owned subsidiary of 1290 ("Subco") will amalgamate (such amalgamated entity to be referred to as "Amalco") which will result in a...

    2021-04-19 8:00 AM EDT
  • Psygen Industries Ltd. and Larose Ventures Ltd. Announce Reverse Takeover Transaction of 1290442 B.C. Ltd. by Psygen Industries Ltd. and Brokered Financing Led by Eight Capital and Canaccord

    Vancouver, British Columbia--(Newsfile Corp. - March 24, 2021) -  Psygen Industries Ltd. ("Psygen") and Larose Ventures Ltd. ("Larose Ventures" or the "Company") are pleased to announce they have entered into a binding letter agreement (the "Letter Agreement") dated March 23, 2021, to complete a business combination by way of a transaction that will constitute a reverse takeover of a wholly-owned subsidiary of the Company, being 1290442 B.C. Ltd. ("SpinCo"), by Psygen (the "Transaction"). The Transaction is conditional on, and will...

    2021-03-24 8:00 AM EDT